Northvale, NJ, United States
Northvale, NJ, United States

Time filter

Source Type

News Article | May 16, 2017
Site: www.prnewswire.com

NORTHVALE, N.J., May 16, 2017 /PRNewswire/ -- Abon Pharmaceuticals, LLC, a specialty pharmaceutical company, today announced that it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Clofarabine Injection, 20 mg/20 mL, Single-use Vial. Clofarabine Injection is a generic equivalent of Genzyme's CLOLAR® Injection, a prescription medicine indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. According to IMS data, the sales for CLOLAR® in 2016 were $67 M. Abon has entered into a distribution agreement with Fresenius Kabi USA to launch the product as First-to-Market generic for CLOLAR®. "This product launch is a significant milestone for Abon" said Salah U. Ahmed, PhD President and CEO of Abon Pharmaceuticals, an independent privately owned LLC. About Abon Pharmaceuticals, LLC. Abon Pharmaceuticals, LLC is a specialty pharmaceutical company that emphasizes science and technology in the development of generic and proprietary products with high formulation barriers. Abon has filed multiple patent applications for drug delivery technologies. To date, six products developed at Abon, have been filed with FDA. This is the third FDA approval of product developed by Abon team and the first approval of an Abon ANDA product.


Patent
Abon Pharmaceuticals LLC | Date: 2016-08-12

The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C_(6)-C_(24 )fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D_(90 )particle size of about 0.5 m to about 25 m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25 C.


Patent
Abon Pharmaceuticals LLC | Date: 2016-10-24

The invention relates to extended-release formulations comprising: (i) a poorly water-soluble active pharmaceutical ingredient; and (ii) a non-aqueous liquid vehicle comprising (a) a hydrophobic lipid comprising a glyceryl ester of a C6-C24 fatty acid, or (b) a hydrophilic organic compound selected from the group consisting of polyethylene glycol, propylene glycol, glycerin, and dimethylsulfoxide, or (c) a combination of (a) and (b), and (iii) an amphiphilic agent wherein the active pharmaceutical ingredient is dispersed as discrete particles having a D90 particle size of about 0.5 m to about 25 m in the formulation, and wherein the formulation is non-gelling and thixotropic with a viscosity of less than 10 poise at a shear rate of 10/s at 25 C.


Wang Z.,Beijing University of Chemical Technology | Lu Y.,Beijing University of Chemical Technology | Liu J.,Beijing University of Chemical Technology | Dang Z.,Beijing University of Chemical Technology | And 2 more authors.
Journal of Applied Polymer Science | Year: 2011

In this article, nano-zinc oxide (ZnO) filled ethylene propylene diene monomer (EPDM) composites are prepared, and the mechanical (static and dynamic) properties and thermal conductivity are investigated respectively, which are further compared with the traditional reinforcing fillers, such as carbon black and nano-silica. Furthermore, influence of in-situ modification (mixing operation assisted by silane at high temperature for a certain time) with the silane-coupling agent Bis-(3-thiethoxy silylpropyl)-tetrasufide (Si69) on the nano-ZnO filled composites is as well investigated. The results indicate that this novel reinforcing filler nano-ZnO can not only perform well in reinforcing EPDM but can also improve the thermal conductivity significantly. In-situ modification with Si69 can enhance the interfacial interaction between nano-ZnO particles and rubber matrix remarkably, and therefore contribute to the better dispersion of filler. As a result, the mechanical properties and the dynamic heat build-up of the nano-ZnO filled composites are improved obviously by in-situ modification, without influencing the thermal conductivity. In comparison with traditioanl reinforcing fillers, in-situ modified nano-ZnO filled composites exhibit the excellent performance in both mechanical (static and dynamic) properties and better thermal conductivity. In general, our work indicates that nano-ZnO, as the novel thermal conductive reinforcing filler, is suitable to prepare elastomer products serving in dynamic conditions, with the longer expected service life. © 2010 Wiley Periodicals, Inc.


Patent
Abon Pharmaceuticals Llc | Date: 2011-05-18

Oral dosage forms for basic amine drugs, the dosage forms having a gastro-retentive component and a non gastro-retentive component. These dosage forms are capable of providing both IR and SR release rates for these drugs. In addition, they provide for release of the drug in the stomach and/or intestine of a mammal to which such dosage forms are administered. Such dosage forms include tablets and capsules. Such dosage forms provide improved bioavailability of otherwise poorly bioavailable basic amine drugs.


Patent
Abon Pharmaceuticals Llc | Date: 2010-10-07

Oral dosage forms for poorly soluble amine drugs are provided. Such dosage forms include an ionizable compound such as an organic acid, an amphiphilic polymer and a release rate-controlling membrane. Such dosage forms allow for the consistent release of the active agent in both gastric pH conditions and in the intestine. Methods of making such dosage forms are also provided.


Patent
Abon Pharmaceuticals Llc | Date: 2016-04-29

This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.


Patent
Abon Pharmaceuticals Llc | Date: 2013-11-14

This invention relates to dosage forms for the delivery of drugs across the oral mucosa having improved transmucosal permeability. More specifically, the invention relates to an oral transmucosal dosage form comprising a primary vehicle comprising a crystallization inhibition agent (CIA) system and a drug, and a secondary vehicle. It also relates to methods of designing and making this dosage form, methods of administering this dosage form and methods of packaging the dosage forms.


Trademark
Abon Pharmaceuticals LLC | Date: 2011-06-14

Pharmaceutical preparations and substances for the treatment of damaged tissue; pharmaceutical preparations and substances for the treatment of diabetes, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, bacterial, metabolic, endocrine, reproductive, menopausal, musculoskeletal, central nervous system, cardiovascular, cardiopulmonary, genitourinary, urological, sexual dysfunction, erectile dysfunction, oncological, hepatological, hematological, genetic, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, auto-immune, and immune system related conditions, diseases and disorders; vaccines; antifungal preparations.


A

Trademark
Abon Pharmaceuticals LLC | Date: 2011-06-14

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of diabetes, infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, bacterial, metabolic, endocrine, reproductive, menopausal, musculoskeletal, central nervous system, cardiovascular, cardiopulmonary, genitourinary, urological, sexual dysfunction, erectile dysfunction, oncological, hepatological, hematological, genetic, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric, auto-immune, and immune system related conditions, diseases and disorders; vaccines; antifungal preparations; pharmaceutical preparations for use in dermatology; cosmeceuticals, namely, medicated skin care preparations.

Loading Abon Pharmaceuticals Llc collaborators
Loading Abon Pharmaceuticals Llc collaborators